Shoulder Innovations (NYSE:SI) CEO Robert Joseph Ball Acquires 6,000 Shares

Key Points

• CEO Robert Joseph Ball of Shoulder Innovations purchased 6,000 shares at an average cost of $15.49, increasing his ownership by 5.70% to a total of 111,259 shares.
• The stock of Shoulder Innovations is currently down 4.7%, trading at $14.97, with a market cap of $227.99 million and a PE ratio of -0.50.
• Analysts maintain a "Moderate Buy" rating for Shoulder Innovations, with an average target price of $19.60, supported by multiple firms giving bullish outlooks.

Shoulder Innovations, Inc. (NYSE:SI - Get Free Report) CEO Robert Joseph Ball purchased 6,000 shares of the business's stock in a transaction dated Friday, September 12th. The stock was bought at an average cost of $15.49 per share, with a total value of $92,940.00. Following the completion of the acquisition, the chief executive officer owned 111,259 shares of the company's stock, valued at approximately $1,723,401.91. The trade was a 5.70% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Robert Joseph Ball also recently made the following trade(s):

• On Thursday, September 11th, Robert Joseph Ball purchased 2,000 shares of Shoulder Innovations stock. The stock was bought at an average cost of $14.90 per share, with a total value of $29,800.00.

Shoulder Innovations Price Performance

Shares of NYSE SI traded up $0.12 during trading on Friday, reaching $14.76. The company had a trading volume of 845,144 shares, compared to its average volume of 157,488. Shoulder Innovations, Inc. has a twelve month low of $11.75 and a twelve month high of $17.94.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on SI. Morgan Stanley began coverage on Shoulder Innovations in a research report on Monday, August 25th. They issued an "overweight" rating and a $18.00 price objective for the company. Wall Street Zen raised Shoulder Innovations from a "sell" rating to a "hold" rating in a research report on Saturday, September 13th. The Goldman Sachs Group began coverage on Shoulder Innovations in a research report on Monday, August 25th. They issued a "buy" rating and a $20.00 price objective for the company. BTIG Research reaffirmed a "buy" rating and issued a $23.00 price objective on shares of Shoulder Innovations in a research report on Tuesday, September 9th. Finally, Piper Sandler began coverage on Shoulder Innovations in a research report on Monday, August 25th. They issued an "overweight" rating and a $18.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $19.60.

Shoulder Innovations Company Profile

We are a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. We currently offer advanced implant systems for shoulder arthroplasty. These systems are a core element of our ecosystem, which we designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain.